Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Datadog Inc (DDOG) vs Medpace Holdings Inc (MEDP) Price & Performance

Datadog IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs Medpace Holdings Inc — how do they compare? Datadog Inc trades at $275 (market cap $96.37B), while Medpace Holdings Inc trades at $536.29 (market cap $15.31B). The key difference: Datadog Inc is far larger — about 6.3× Medpace Holdings Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.

DDOGMEDP
Market Cap
$96.37B$15.31B
Sector
TechnologyTechnology
52-Week High
$277.49$620.59
52-Week Low
$102.62$308.88
Enterprise Value
$92.90B$14.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $260.24, up 1.05% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.58. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margin is modest at 3.69%. The company's acquisition of Adaptive ML aims to bolster its AI capabilities, positioning it for sustained growth in cloud observability.

The outlook for DDOG is positive, driven by solid revenue expansion and strategic AI investments, but high valuation multiples (P/E of 667.28, P/S of 25.79) pose risks if growth slows. Investor sentiment is overwhelmingly bullish, with 83% of analysts rating it a buy, though competition and market volatility require monitoring. The stock's momentum and institutional backing suggest further upside, contingent on continued execution and market conditions.

Medpace Holdings Inc

MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.

Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP